

ATTACHMENT A: DPA STATEMENT OF FACTS

The following DPA Statement of Facts is incorporated by reference as part of the Deferred Prosecution Agreement (this “Agreement”) between the United States Attorney’s Office for the District of Massachusetts and the United States Department of Justice, Consumer Protection Branch (collectively, the “Government”) and AEGERION PHARMACEUTICALS, INC. (“AEGERION”). AEGERION hereby agrees and stipulates that the following information is true and accurate. AEGERION admits, accepts, and acknowledges that it is responsible for the acts of its officers, directors, employees, and agents as set forth below. Should the Government pursue the prosecution that is deferred by this Agreement, AEGERION agrees that it will neither contest the admissibility of, nor contradict, this DPA Statement of Facts in any such proceeding. The following facts establish beyond a reasonable doubt the charge set forth in the HIPAA Information deferred by this Agreement:

1. From at least January 2013, and continuing through in or about 2015, within the District of Massachusetts, and elsewhere, AEGERION PHARMACEUTICALS, INC. (“AEGERION acting by and through certain of its officers and employees in concert with certain non-AEGERION health professionals, known and unknown, did knowingly conspire, confederate, and agree to violate the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), Title 42, United States Code, Sections 1320d-6(a) and 6(b)(3), by knowingly using and causing to be used unique health identifiers, obtaining individually identifiable health information relating to individuals, and disclosing individually identifiable health information to another person, without patient authorization required by 45 C.F.R. § 164.508(a)(3), with the intent to sell, transfer, or use individually identifiable health information for commercial advantage, personal gain, or malicious harm.

2. At all relevant times, the defendant, AEGERION, was a Delaware corporation with a principal place of business in Cambridge, Massachusetts, and from 2013 to 2015 manufactured and sold the drug Juxtapid (generic name: lomitapide).

3. The U.S. Food and Drug Administration (“FDA”) approved Juxtapid with an indication for use as an adjunct to a low-fat diet and other lipid-lowering treatments to reduce cholesterol in patients with a rare genetic disorder called homozygous familial hypercholesterolemia, or “HoFH.”

4. HIPAA was enacted, among other things, to limit the circumstances in which patients’ confidential medical information (“individually identifiable health information” or “protected health information”) could be used or disclosed. HIPAA regulations specifically forbid disclosure or use of individually identifiable health information for marketing without written patient authorization. 45 C.F.R. § 164.508(a)(3). HIPAA and the privacy regulations apply to health plans, health care clearinghouses, and health care providers who transmit any health information in electronic form in connection with a transaction covered by the law and privacy regulations. *See* 45 C.F.R. §§ 160.102(a) and 103 (defining “covered entity”).

5. AEGERION officers and sales employees frequently called on physicians, attempting to convince them to prescribe Juxtapid. These physicians maintained records for patients which contained protected health information. Because these physicians were health care providers who transmitted patients’ protected health information in electronic form, they were covered by HIPAA and associated privacy regulations.

6. At all times relevant to this DPA Statement of Facts, AEGERION officers and sales employees knew that they could not access HIPAA-protected patient information held by physicians without written patient authorizations.

7. AEGERION's sales employees were not trained medical professionals and were at no time relevant to this DPA Statement of Facts qualified or able to provide medical treatment to patients or to assist physicians in providing medical treatment.

8. Nevertheless, to market Juxtapid to doctors with patients not previously diagnosed with HoFH, non-medical AEGERION officers and sales employees involved in the sales and marketing of Juxtapid sought to obtain and did obtain and use patients' protected health information possessed by physicians and their medical staff, without patient authorizations required by HIPAA regulations, for the purpose of marketing Juxtapid to physicians and, at times, directly to patients.

9. Without obtaining required HIPAA authorizations, many AEGERION sales employees gained access to physicians' electronic medical record ("EMR") systems to perform searches to identify patients for whose treatment they could market Juxtapid to physicians and, at times, directly to patients.

10. Many AEGERION sales employees gained access to protected health information without patient authorization to complete or to assist with the completion of statements of medical necessity to support insurance coverage of prescriptions for Juxtapid.

11. Many AEGERION sales employees used protected health information obtained from physicians without patient authorization to contact patients to convince them to start Juxtapid therapy.

12. Many AEGERION sales employees also used protected health information obtained from physicians without patient authorization to contact patients in order to obtain authorization from patients to allow AEGERION customer service personnel to access those patients' protected health information.

13. Several AEGERION sales employees forged signatures on patient authorizations.

14. One AEGERION sales representative obtained patient signatures on HIPAA authorizations, written in English, from non-English speaking patients who did not understand the nature of the HIPAA release.

15. AEGERION sales employees gained access to patients' HIPAA-protected health information without patient authorization for sales and marketing purposes at the direction of and with the approval of AEGERION's senior management.

16. One AEGERION sales executive encouraged AEGERION sales employees to wear surgical scrubs instead of business attire when visiting physicians' offices in order to facilitate access to HIPAA-protected health information and to patients.

17. In February 2013, certain AEGERION managers paired with AEGERION sales employees in a competition for the most new prescriptions in a single day. During the competition, AEGERION managers and employees obtained and used patients' protected health information without patient authorization, including prescriptions for identified patients; one senior AEGERION manager sent a picture of two prescriptions (for pediatric patients without any patient authorization for access to HIPAA-protected health information) and of an EMR query report from a physician's office including approximately 250 identifiable patients (without any patient authorizations) to the AEGERION sales teams to show his success with his sales representative partner in marketing Juxtapid.

18. In May 2013, an AEGERION manager told the AEGERION sales force to contact patients who had not authorized direct contact in order to obtain HIPAA releases.

19. AEGERION also conducted “kickers” or bonus sales commission incentive programs for its sales employees, with one of the success criteria being the conversion of non-consented patients to consented patients within five days of obtaining a prescription for Juxtapid.

20. Some AEGERION sales employees also gave gifts or provided benefits to medical staff in exchange for access to patient data, all in furtherance of marketing Juxtapid to physicians.

21. As a result of AEGERION’s efforts to obtain and success in obtaining HIPAA-protected health information from physicians without patient authorization for hundreds of individuals, including patients under 18 years of age, AEGERION marketed Juxtapid to numerous physicians and patients, all for the purpose of commercial gain to AEGERION.

ATTACHMENT B: COMPLIANCE PROGRAM AND CERTIFICATIONS

Aegerion Pharmaceuticals, Inc. (“Aegerion”) agrees to the provisions set forth in this Attachment, which is incorporated by reference as part of the Deferred Prosecution Agreement (the “Agreement”) between the United States Attorney’s Office for the District of Massachusetts and the United States Department of Justice, Consumer Protection Branch (collectively, “the Government”) and Aegerion. Aegerion recognizes that each of the terms in this Attachment constitutes a material term of the Deferred Prosecution Agreement.

Compliance and Ethics Program

1. Aegerion will maintain a Compliance and Ethics Program that governs Aegerion’s business operations. The purpose of the Compliance and Ethics Program is to (a) prevent, detect, and correct violations of law and company policy and procedures; (b) assure the continuation of compliance-related policies and procedures for business operations; (c) assure the continued development of training and other programs designed to educate employees regarding applicable policies, procedures, and standards; (d) conduct auditing and monitoring of the effectiveness of applicable policies, procedures, and standards; (e) assure that there is a mechanism for internal reporting of questionable or inappropriate activities to enable timely investigation and resolution; and (f) assure that appropriate corrective action is taken to prevent recurrence of misconduct.

2. Aegerion’s Compliance and Ethics Program will consist of a Vice President Ethics and Compliance (“Compliance Officer”) who reports to the President of Aegerion and the Global Chief Compliance Officer of Novilion Therapeutics Inc.; a Compliance Committee composed of Aegerion management (e.g., executives of relevant departments) that meets at least quarterly; a comprehensive set of written compliance policies and procedures governing the

conduct of its employees; a training program focused on the company's compliance policies and procedures; a disclosure program to allow employees to report potential violations of law or the company's compliance policies and procedures; a non-retaliation policy; and a monitoring and auditing program designed to deter and detect compliance issues. The Compliance Officer is responsible for overseeing the administration and implementation of the Compliance and Ethics Program. The Compliance Officer reports at least quarterly on the Compliance and Ethics Program to the Compliance Committee. The Compliance Officer has direct access to senior executives vested with the authority to direct and implement compliance-related changes in Aegerion as necessary. The Compliance Officer has the authority to exercise independent judgment in assessing compliance-related matters. The Compliance Officer has authority to seek advice from outside legal counsel or other outside experts when appropriate. The Compliance Officer is authorized to report issues of any kind directly to the Board of Directors of Novilion Therapeutics Inc. (or a Committee thereof).

3. The Compliance and Ethics Program will include and maintain compliance policies and procedures designed to prevent, detect, and correct violations of HIPAA and its associated privacy regulations, including, but not limited to, the following subjects:

- a. *Impermissible Access to Patient Information:* Aegerion will implement and maintain a policy prohibiting its sales agents from accessing and reviewing patient information (or otherwise consulting with health care providers) to identify potential patients for treatment with Aegerion's products without patient consent as required by HIPAA or otherwise permitted under HIPAA.

- b. *Sales Compensation and Incentives:* Aegerion will establish and maintain policies and procedures that shall require that financial incentives do not improperly motivate field-facing sales representatives or their direct managers to engage in improper promotion, sales, and marketing of Aegerion's products (including accessing protected health information or representing themselves to be involved in the diagnosis and treatment of patients). Aegerion shall exclude from incentive compensation any sales under circumstances indicating that improper promotion of Aegerion's products occurred, such as the impermissible accessing of protected patient information, and shall not offer or provide any other financial reward to its sales representatives or their managers based upon or involving patient authorization of Aegerion's access to protected health information.

Notice to Health Care Providers and Entities

4. Within sixty (60) days after the Effective Date of this Agreement, Aegerion shall send, by first class mail, postage prepaid with delivery confirmation, a notice containing the language set forth below to all health care providers (a) who are or who have previously been certified to prescribe Juxtapid under the Juxtapid REMS program, (b) who submitted a prescription for Juxtapid, (c) who made a medical information request concerning Juxtapid, (d) who participated in an Aegerion-sponsored speaker program concerning Juxtapid, or (e) who submitted a grant proposal concerning Juxtapid. This notice shall be dated and shall be signed by Aegerion's Board Chair. The body of the notice shall state the following:

As you may be aware, Aegerion Pharmaceuticals, Inc. recently entered into civil, criminal, and administrative settlements with the United States

of America and individual states in connection with Aegerion's promotion of its product Juxtapid. This letter provides you with additional information about the global settlement, explains Aegerion's commitments going forward, and tells you how to obtain more information about those commitments.

Aegerion pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act and agreed to pay approximately \$7 million in criminal fines and forfeiture. Aegerion also entered into a three-year Deferred Prosecution Agreement to resolve claims that it violated the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Separately, Aegerion agreed to enter into a Civil Consent Decree of Permanent Injunction to be monitored by the U.S. Food and Drug Administration (FDA).

In addition, the federal government and several individual states alleged that Aegerion's conduct violated the federal False Claims Act and equivalent state statutes. To resolve those allegations, Aegerion entered into a separate civil False Claims Act settlement whereby Aegerion agreed to reimburse federal and state health care programs approximately \$29 million. As part of the settlement, Aegerion also entered into a five-year corporate integrity agreement with the Office of Inspector General of the U.S. Department of Health and Human Services.

Finally, the Securities and Exchange Commission alleged that Aegerion's conduct violated federal security statutes. To resolve those allegations, Aegerion entered into a separate civil securities settlement whereby Aegerion agreed to pay approximately \$4 million.

More information about these settlements may be found at the following websites:

https://www.justice.gov/civil/current-and-recent-cases#_Pharm2

<http://oig.hhs.gov/fraud/cia/index.html>

Please call Aegerion at 1-855-463-8974 or visit us at <http://novelion.com/about-novelion/aegerion-pharmaceuticals/aegeriongovernment-settlement> if you have questions about the settlement referenced above. Please call Aegerion at 1-855-233-8089 or visit us at <https://novelioncompliance.tnwreports.com> to report any instances in which you believe that an Aegerion representative inappropriately promoted a product or engaged in other questionable conduct.

5. The Compliance Officer (or a designee) shall maintain a log (the "Log") of all calls and messages received by the Compliance and Ethics Program through its disclosure

program that report questionable practices by Aegerion employees concerning HIPAA and associated privacy regulations, including any such calls or messages made in response to the notice above. The Log shall include a record and summary of each call and message received (whether anonymous or not), the status of the call or message, and any corrective action taken in response to the call or message. Aegerion shall produce the Log to the United States within fourteen (14) days of a written request for such production.

Certifications and Board Resolution

6. Aegerion will conduct the reviews described in Paragraphs 7 through 9 below for each of three (3) Review Periods. The duration of the first and second Review Periods each will be one year, beginning with the first one-year period following the Effective Date of this Agreement. The duration of the third Review Period will be nine months. Aegerion will provide the certifications and resolutions described in Paragraphs 7 through 9 below to the Government within one hundred twenty (120) days following the end of each of the first and second Review Periods, and within sixty (60) days following the end of the third Review Period.

7. Following the end of each Review Period, the Compliance Officer shall conduct a review of the Log described in Paragraph 5 above for the preceding Review Period. Based on his or her review, the Compliance Officer shall submit to the Government a signed certification (the "Log Certification") (a) stating that, to the best of his or her knowledge, during the preceding Review Period, Aegerion maintained the Log pursuant to this Agreement; and (b) stating the total number of calls and messages received by the Compliance and Ethics Program through its disclosure program, including any such calls or messages made in response to the notice in Paragraph 4, and the number of those calls and messages that relate to HIPAA and its associated privacy regulations for each month of the preceding Review Period.

8. Following the end of each Review Period, the President of Aegerion shall conduct a review of the effectiveness of the Compliance and Ethics Program for the preceding Review Period. Based on his or her review, the President of Aegerion shall submit to the Government a signed certification stating that, to the best of his or her knowledge based on a reasonable inquiry, during the preceding Review Period, the Compliance and Ethics Program was effective in identifying and preventing violations of federal health care program requirements, HIPAA, and associated privacy regulations. The certification shall summarize the review described above. If the President of Aegerion is unable to certify that the Compliance and Ethics Program was effective in preventing violations of federal health care program requirements, HIPAA, and associated privacy regulations, he or she shall provide a detailed explanation of why the Compliance and Ethics Program was not effective, and will state the steps Aegerion is taking to ensure the effectiveness of the Compliance and Ethics program.

9. Following the end of each Review Period, the Board of Directors of Novelion Therapeutics Inc. (or any future parent company of Aegerion), or a designated Committee thereof (the "Board"), shall conduct a review of the effectiveness of the Compliance and Ethics Program for the preceding Review Period. This review shall include, but not be limited to, updates and reports by the Compliance Officer and other personnel regarding compliance matters. The Board shall evaluate the effectiveness of the Compliance and Ethics Program, including, at a minimum, by receiving updates about the activities of the Compliance Officer and Compliance Committee and updates about the adoption and implementation of policies, procedures, and practices to ensure compliance with applicable federal health care program requirements, HIPAA, and associated privacy regulations. Based on its review, the Board shall

submit to the Government a resolution that summarizes its review and oversight as set forth above and that includes, at a minimum, the following language:

The Board of Directors of Novelion Therapeutics Inc. [or any future parent company of Aegerion] (or a designated Committee of the Board) has made a reasonable inquiry as described in Attachment B of the Deferred Prosecution Agreement with Aegerion into the operations of the Compliance and Ethics Program for the preceding Review Period, [insert date range], including the performance of the Compliance Officer and the Compliance Committee. Based on its reasonable inquiry and review, the Board has concluded that, to the best of its knowledge, Aegerion has implemented an effective compliance program, as defined in the United States Sentencing Commission Guidelines Manual, Chapter 8: Sentencing of Organizations, to meet the requirements of federal health care programs, the Health Insurance Portability and Accountability Act of 1996 and its associated privacy regulations, and as set forth in the Deferred Prosecution Agreement.

If the Board is unable to provide any part of this statement, it shall include in the resolution a written explanation of the reasons why it is unable to provide such a statement.

10. Aegerion agrees that, in the event that the Government shortens or extends the Term of this Agreement pursuant to Paragraph 3 of the Deferred Prosecution Agreement, an increase or decrease in the duration of the Review Periods described in Paragraph 6 above, and an increase or decrease in the total number of reviews required by Paragraphs 7 through 9 above, may be required by the Government, in its sole discretion, and upon notice to Aegerion.

Additional Reporting Obligations

11. Fifteen (15) days after the end of each calendar quarter (that is, by January 15 for the calendar quarter ending December 31, April 15 for the calendar quarter ending March 31, July 15 for the calendar quarter ending June 30, and October 15 for the calendar quarter ending September 30), excepting any calendar quarter that ends within sixty (60) days of the end of the Term of this Agreement, Aegerion shall submit a report to the Government in writing stating whether any Reportable Events have been determined to have occurred during the preceding

calendar quarter, and providing updated information about Reportable Events that Aegerion determined to have occurred during any prior calendar quarter, as may be necessary in the reasonable determination of Aegerion or at the Government's request. A Reportable Event is any matter that, after a reasonable opportunity to conduct an appropriate review or investigation of the allegations, a reasonable person would consider a probable violation of HIPAA, 42 U.S.C. § 1320d-6, and its associated privacy regulations. A Reportable Event may be the result of an isolated event or a series of occurrences. The written report to the Government shall include: (a) a description of the Reportable Event, including the relevant facts, the positions of the persons involved, and the legal authorities implicated; (b) a description of Aegerion's actions taken to investigate and correct the Reportable Event; and (c) a description of any further steps Aegerion plans to take to address the Reportable Event and prevent it from recurring. The Compliance Officer shall promptly report to the President of Aegerion any Reportable Event determined to have occurred by Aegerion. The Compliance Officer shall directly and promptly report to the Board (or a designated Committee of the Board), and record in writing, any allegation concerning a Reportable Event that involves any Aegerion employee with senior managerial responsibilities.

Filing of Certifications, Resolutions, and Reports¹

12. The certifications referenced above in Paragraphs 7 and 8 above shall be sworn to under penalty of perjury and shall set forth that the representations contained therein may be

¹ Consistent with the U.S. Department of Justice's Freedom of Information Act ("FOIA") procedures, the Government shall make reasonable effort to notify Aegerion prior to any release by the Department of Justice of information submitted by Aegerion pursuant to its obligations under this Plea Agreement and identified upon submission of Aegerion as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Aegerion shall have the rights set forth under said procedures.

provided to, relied upon, and material to the government of the United States, and that a knowing false statement could result in criminal or civil liability for the signatory.

13. Aegerion may submit a timely written request for an extension of time to provide the certifications, resolutions, or reports required by Paragraphs 6 through 9 and Paragraph 11 above. A written request is timely if it is received by the U.S. Attorney's Office for the District of Massachusetts and the Consumer Protection Branch, U.S. Department of Justice, at least five business days prior to the date by which the certification, resolution or report is due. Timely requests for extension will not be unreasonably denied. If an extension of time is granted in writing, Stipulated Penalties as described in Paragraph 16 of the Deferred Prosecution Agreement shall not accrue until one day after Aegerion fails to meet the revised deadline. If not granted, Stipulated Penalties shall not begin to accrue until three (3) business days after Aegerion received the Government's written denial of such request or the original deadline, whichever is later.

ATTACHMENT C: CERTIFICATE OF CORPORATE RESOLUTIONS

WHEREAS, Aegerion Pharmaceuticals, Inc. (“Aegerion”) has been engaged in discussions with the United States Attorney’s Office for the District of Massachusetts and the United States Department of Justice, Consumer Protection Branch (collectively, the “United States”) regarding issues arising in relation to its sale and distribution of the drug, Juxtapid; and

WHEREAS, in order to resolve such discussions, it is proposed that Aegerion enter into a certain agreement with the Government; and

WHEREAS, outside counsel for Aegerion has advised the Board of Directors of Aegerion of its rights, possible defenses, the U.S. Sentencing Guidelines’ provisions, and the consequences of entering into such agreement with the United States;

Therefore, the Board of Directors has RESOLVED that:

1. Aegerion (a) acknowledges the filing of the one-count Information charging Aegerion with conspiracy to violate Title 42, United States Code, Sections 1320d-6(a) and 6(b)(3), in violation of Title 18, United States Code, Section 371; and (b) waives indictment on such charges and enters into a deferred prosecution agreement with the United States.

2. Aegerion accepts the terms and conditions of this Agreement, including, but not limited to, (a) a knowing waiver of its rights to a speedy trial pursuant to the Sixth Amendment to the United States Constitution, Title 18, United States Code, Section 3161, and Federal Rule of Criminal Procedure 48(b); (b) a knowing waiver for purposes of this Agreement and any charges by the United States arising out of the conduct described in the attached Statement of Facts of any objection with respect to venue and consent to the filing of the Information, as provided under the terms of this Agreement, in the United States District Court for the District of Massachusetts; and (c) a knowing waiver of any defenses based on the statute of limitations for

any prosecution relating to the conduct described in the attached Statement of Facts or relating to conduct known to the United States prior to the date on which this Agreement was signed that is not time-barred by the applicable statute of limitations on the date of the signing of this Agreement;

3. The Vice President, Corporate Counsel of Aegerion, Jennifer Fitzpatrick, is hereby authorized, empowered and directed, on behalf of Aegerion to execute the Deferred Prosecution Agreement substantially in such form as reviewed by this Board of Directors at this meeting with such changes as the Vice President, Corporate Counsel of Aegerion, Jennifer Fitzpatrick, may approve;

4. The Vice President, Corporate Counsel of Aegerion, Jennifer Fitzpatrick, is hereby authorized, empowered and directed to take any and all actions as may be necessary or appropriate and to approve the forms, terms or provisions of any agreement or other documents as may be necessary or appropriate, to carry out and effectuate the purpose and intent of the foregoing resolutions; and

5. All of the actions of the Vice President, Corporate Counsel of Aegerion, Jennifer Fitzpatrick, which actions would have been authorized by the foregoing resolutions except that such actions were taken prior to the adoption of such resolutions, are hereby severally ratified, confirmed, approved, and adopted as actions on behalf of Aegerion.

Date: 9/14/17

By: Barbara Chan

Barbara Chan
President
Aegerion Pharmaceuticals, Inc.